Search Results - "Favalli, Ennio G."

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis by Favalli, Ennio G.

“…Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disorder involving inflammation and progressive destruction of the joints, affecting up to 1%…”
Get full text

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review by Baraliakos, Xenofon, Gensler, Lianne S., D’Angelo, Salvatore, Iannone, Florenzo, Favalli, Ennio G., de Peyrecave, Natasha, Auteri, Simone E., Caporali, Roberto

“…We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score…”
Get full text

Baricitinib for COVID-19: a suitable treatment? by Favalli, Ennio G, Biggioggero, Martina, Maioli, Gabriella, Caporali, Roberto

Get full text

Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry by Favalli, Ennio G., Sinigaglia, Luigi, Becciolini, Andrea, Grosso, Vittorio, Gorla, Roberto, Bazzani, Chiara, Atzeni, Fabiola, Sarzi Puttini, Pier C., Fusaro, Enrico, Pellerito, Raffaele, Caporali, Roberto

“…Objectives To evaluate the 2‐year retention rate of golimumab compared with etanercept and adalimumab as second‐line biologic agent in rheumatoid arthritis…”
Get full text

Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review by Gossec, Laure, Bessette, Louis, Xavier, Ricardo M, Favalli, Ennio G, Östör, Andrew, Buch, Maya H

“…Treat-to-target (T2T) is recommended in the management of rheumatoid arthritis (RA) but its implementation is suboptimal. We aimed to identify interventional…”
Get full text

Secukinumab in HLA‐B27 associated uveitis by Miserocchi, Elisabetta, Giuffre, Chiara, Caporali, Roberto, Favalli, Ennio G.

Get full text

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries by Michelsen, Brigitte, Georgiadis, Stylianos, Di Giuseppe, Daniela, Loft, Anne G., Nissen, Michael J., Iannone, Florenzo, Pombo‐Suarez, Manuel, Mann, Herman, Rotar, Ziga, Eklund, Kari K., Kvien, Tore K., Santos, Maria J., Gudbjornsson, Bjorn, Codreanu, Catalin, Yilmaz, Sema, Wallman, Johan K., Brahe, Cecilie H., Möller, Burkhard, Favalli, Ennio G., Sánchez‐Piedra, Carlos, Nekvindova, Lucie, Tomsic, Matija, Trokovic, Nina, Kristianslund, Eirik K., Santos, Helena, Löve, Thorvardur J., Ionescu, Ruxandra, Pehlivan, Yavuz, Jones, Gareth T., Horst‐Bruinsma, Irene, Ørnbjerg, Lykke M., Østergaard, Mikkel, Hetland, Merete L.

“…Objective There is a lack of real‐life studies on interleukin‐17 (IL‐17) inhibition in psoriatic arthritis (PsA). We assessed real‐life 6‐ and 12‐month…”
Get full text

Biomarkers in psoriatic arthritis: a systematic literature review by Generali, Elena, Scirè, Carlo A, Favalli, Ennio G, Selmi, Carlo

“…Psoriatic arthritis (PsA) is characterized by chronic inflammation of peripheral joints and axial skeleton, associated with a strong genetic background…”
Get more information

Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA by Iannone, Florenzo, Favalli, Ennio G., Caporali, Roberto, D’Angelo, Salvatore, Cantatore, Francesco Paolo, Sarzi-Puttini, Piercarlo, Foti, Rosario, Conti, Fabrizio, Carletto, Antonio, Gremese, Elisa, Cauli, Alberto, Ramonda, Roberta, Palermo, Adalgisa, Epis, Oscar, Priora, Marta, Bergossi, Francesca, Frediani, Bruno, Salaffi, Fausto, Lopalco, Giuseppe, Cacciapaglia, Fabio, Marchesoni, Antonio, Biggioggiero, Martina, Bugatti, Serena, Balduzzi, Silvia, Carriero, Antonio, Corrado, Addolorata, Bongiovanni, Sara, Benenati, Alessia, Miranda, Francesca, Fracassi, Elena, Perra, Daniela, Ferraccioli, Gianfranco, Lapadula, Giovanni

“…•In a large cohort of patients with SpA and PsA from the real life, golimumab has shown to be as effective in 1-biologic IR as in biologic-naive patients, with…”
Get full text

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry by Manara, Maria, Caporali, Roberto, Favalli, Ennio G, Grosso, Vittorio, Atzeni, Fabiola, Sarzi Puttini, Piercarlo, Gorla, Roberto, Bazzani, Chiara, Fusaro, Enrico, Pellerito, Raffaele, Rocchetta, Pier Andrea, Sinigaglia, Luigi

“…We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre…”
Get full text

Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort by Favalli, Ennio G., Becciolini, Andrea, Carletto, Antonio, Conti, Fabrizio, Amato, Giorgio, Fusaro, Enrico, Quartuccio, Luca, Egan, Colin Gerard, Lo Monaco, Andrea, Benucci, Maurizio, Salaffi, Fausto, Semeraro, Angelo, Parisi, Simone, Ceccarelli, Fulvia, Piazza, Ilaria, Foti, Rosario

“…Few studies have compared the efficacy of switching from etanercept to adalimumab in the real-life setting in rheumatoid arthritis (RA) and psoriatic arthritis…”
Get full text

Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review by van der Horst-Bruinsma, Irene E., Robinson, Philip C., Favalli, Ennio G., Verbraak, Frank D., Kim, Mindy, Kumke, Thomas, Bauer, Lars, Hoepken, Bengt, Deodhar, Atul

“…Background Acute anterior uveitis (AAU) affects up to 40% of patients with axial spondyloarthritis (axSpA). An effective treatment for patients with axSpA that…”
Get full text

How advances in personalized medicine will change rheumatology by Selmi, Carlo, Kon, Elizaveta, De Santis, Maria, Favalli, Ennio G, Cimaz, Rolando, Generali, Elena, Sinigaglia, Luigi

Get more information

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) by Scarpato, Salvatore, Antivalle, Marco, Favalli, Ennio G., Nacci, Francesca, Frigelli, Sabrina, Bartoli, Francesca, Bazzichi, Laura, Minisola, Giovanni, Matucci Cerinic, Marco

“…Objective. To identify the determinants of anti-TNF-naive patients’ preferences for the route of administration of anti-TNF agents. Methods. The study was…”
Get full text

Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety by Favalli, Ennio G, Caporali, Roberto, Sinigaglia, Luigi, Pipitone, Nicolo', Miniati, Irene, Montecucco, Carlomaurizio, Matucci-Cerinic, Marco

“…Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific…”
Get full text

51558 Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies by Merola, Joseph F., Gottlieb, Alice B., Ink, Barbara, Bajracharya, Rajan, Lambert, Jérémy, Coarse, Jason, Favalli, Ennio G.

Get full text

E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study by Tillett, William R, Merola, Joseph F, Tanaka, Yoshiya, Favalli, Ennio G, McGonagle, Dennis, Walsh, Jessica A, Thaçi, Diamant, Ink, Barbara, Bajracharya, Rajan, Taieb, Vanessa, Ritchlin, Christopher T

“…Abstract Background/Aims Given the chronic nature of psoriatic arthritis (PsA), sustaining high levels of disease control with treatment is important…”
Get full text

E069 Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study by Tillett, William R, Merola, Joseph F, Tanaka, Yoshiya, Favalli, Ennio G, McGonagle, Dennis, Thaçi, Diamant, Walsh, Jessica A, Ink, Barbara, Bajracharya, Rajan, Coarse, Jason, Ritchlin, Christopher T

“…Abstract Background/Aims Psoriatic arthritis (PsA) is a chronic disease affecting multiple domains; however, patients can experience loss of response with…”
Get full text